Outcomes of patients aged ≥80 years with respiratory failure initially treated with non-invasive ventilation in European intensive care units before and during COVID-19 pandemic.
COVID-19
Intensive care unit
Non-invasive ventilation
Older patients
Respiratory failure
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
12 Sep 2023
12 Sep 2023
Historique:
received:
03
06
2023
accepted:
16
08
2023
medline:
12
9
2023
pubmed:
12
9
2023
entrez:
12
9
2023
Statut:
epublish
Résumé
Non-invasive ventilation (NIV) has been commonly used to treat acute respiratory failure due to COVID-19. In this study we aimed to compare outcomes of older critically ill patients treated with NIV before and during the COVID-19 pandemic. We analysed a merged cohort of older adults admitted to intensive care units (ICUs) due to respiratory failure. Patients were enrolled into one of two prospective observational studies: before COVID-19 (VIP2-2018 to 2019) and admitted due to COVID-19 (COVIP-March 2020 to January 2023). The outcomes included: 30-day mortality, intubation rate and NIV failure (death or intubation within 30 days). The final cohort included 1986 patients (1292 from VIP2, 694 from COVIP) with a median age of 83 years. NIV was used as a primary mode of respiratory support in 697 participants (35.1%). ICU admission due to COVID-19 was associated with an increased 30-day mortality (65.5% vs. 36.5%, HR 2.18, 95% CI 1.71 to 2.77), more frequent intubation (36.9% vs. 17.5%, OR 2.63, 95% CI 1.74 to 3.99) and NIV failure (76.2% vs. 45.3%, OR 4.21, 95% CI 2.84 to 6.34) compared to non-COVID causes of respiratory failure. Sensitivity analysis after exclusion of patients in whom life supporting treatment limitation was introduced during primary NIV confirmed higher 30-day mortality in patients with COVID-19 (52.5% vs. 23.4%, HR 2.64, 95% CI 1.83 to 3.80). The outcomes of patients aged ≥80 years treated with NIV during COVID-19 pandemic were worse compared then those treated with NIV in the pre-pandemic era.
Sections du résumé
BACKGROUND
BACKGROUND
Non-invasive ventilation (NIV) has been commonly used to treat acute respiratory failure due to COVID-19. In this study we aimed to compare outcomes of older critically ill patients treated with NIV before and during the COVID-19 pandemic.
METHODS
METHODS
We analysed a merged cohort of older adults admitted to intensive care units (ICUs) due to respiratory failure. Patients were enrolled into one of two prospective observational studies: before COVID-19 (VIP2-2018 to 2019) and admitted due to COVID-19 (COVIP-March 2020 to January 2023). The outcomes included: 30-day mortality, intubation rate and NIV failure (death or intubation within 30 days).
RESULTS
RESULTS
The final cohort included 1986 patients (1292 from VIP2, 694 from COVIP) with a median age of 83 years. NIV was used as a primary mode of respiratory support in 697 participants (35.1%). ICU admission due to COVID-19 was associated with an increased 30-day mortality (65.5% vs. 36.5%, HR 2.18, 95% CI 1.71 to 2.77), more frequent intubation (36.9% vs. 17.5%, OR 2.63, 95% CI 1.74 to 3.99) and NIV failure (76.2% vs. 45.3%, OR 4.21, 95% CI 2.84 to 6.34) compared to non-COVID causes of respiratory failure. Sensitivity analysis after exclusion of patients in whom life supporting treatment limitation was introduced during primary NIV confirmed higher 30-day mortality in patients with COVID-19 (52.5% vs. 23.4%, HR 2.64, 95% CI 1.83 to 3.80).
CONCLUSION
CONCLUSIONS
The outcomes of patients aged ≥80 years treated with NIV during COVID-19 pandemic were worse compared then those treated with NIV in the pre-pandemic era.
Identifiants
pubmed: 37698708
doi: 10.1186/s13613-023-01173-2
pii: 10.1186/s13613-023-01173-2
pmc: PMC10497468
doi:
Types de publication
Journal Article
Langues
eng
Pagination
82Informations de copyright
© 2023. La Société de Réanimation de Langue Francaise = The French Society of Intensive Care (SRLF).
Références
Intensive Care Med. 2020 Jan;46(1):57-69
pubmed: 31784798
Lancet Respir Med. 2021 Jun;9(6):622-642
pubmed: 33965003
Crit Care. 2021 Jul 30;25(1):268
pubmed: 34330320
BMC Med Ethics. 2019 Jun 3;20(1):39
pubmed: 31159853
Am J Respir Crit Care Med. 2017 Jan 1;195(1):67-77
pubmed: 27753501
Lancet Respir Med. 2014 May;2(5):380-6
pubmed: 24740011
Anaesthesiol Intensive Ther. 2018;50(4):245-251
pubmed: 30242826
Crit Care. 2022 Jul 22;26(1):224
pubmed: 35869557
JAMA. 2022 Sep 20;328(11):1063-1072
pubmed: 36125473
Crit Care. 2021 Apr 19;25(1):149
pubmed: 33874987
JAMA. 2021 May 4;325(17):1731-1743
pubmed: 33764378
N Engl J Med. 2020 May 21;382(21):2049-2055
pubmed: 32202722
Crit Care. 2021 Jul 1;25(1):231
pubmed: 34210358
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Intensive Care Med. 2023 Jul;49(7):727-759
pubmed: 37326646
Intensive Care Med. 2017 Dec;43(12):1820-1828
pubmed: 28936626
Minerva Med. 2019 Dec;110(6):555-563
pubmed: 31359741
J Intensive Care. 2022 Jul 8;10(1):32
pubmed: 35799288
Intensive Care Med. 2022 Apr;48(4):435-447
pubmed: 35218366
Br J Anaesth. 2021 Sep;127(3):353-364
pubmed: 34217468
CMAJ. 2021 May 25;193(21):E761-E768
pubmed: 34035056
JAMA. 2022 Feb 8;327(6):546-558
pubmed: 35072713
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Eur Respir J. 2017 Aug 31;50(2):
pubmed: 28860265
J Crit Care. 2022 Apr;68:76-82
pubmed: 34929530
JAMA. 2020 Jun 9;323(22):2329-2330
pubmed: 32329799
J Am Geriatr Soc. 2023 May;71(5):1440-1451
pubmed: 36751883
Anaesthesiol Intensive Ther. 2021;53(4):290-295
pubmed: 35257561